GlassScriptPhysician profile
Alan D Langerak
NPI 1902853294
$8,730.75
in general payments reported to CMS, 2019-2025
66 companies · $2,732 in 2025
The $2,732 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,182 · 2020: $414 · 2021: $107 · 2022: $288 · 2023: $591 · 2024: $2,417 · 2025: $2,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,473.06 |
| Education | $266.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $649.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $513.30 | 2019-2025 | Lynparza, Imfinzi |
| Seagen INC. | $476.94 | 2019-2023 | Tukysa, Padcev, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $439.89 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $431.83 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $422.26 | 2019-2025 | |
| Janssen Biotech, INC. | $411.20 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Abbvie INC. | $324.53 | 2019-2025 | |
| Genmab U.S., INC. | $307.81 | 2023-2025 | Epkinly, Tivdak |
| Lilly USA, LLC | $300.41 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $262.52 | 2019-2022 | |
| Genzyme Corporation | $257.44 | 2019-2025 | |
| Celgene Corporation | $231.98 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Daiichi Sankyo INC. | $230.83 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Incyte Corporation | $220.42 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $215.27 | 2022-2025 | |
| Eisai INC. | $194.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.68 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $168.63 | 2019-2023 | Epkinly, Imbruvica |
| Gilead Sciences, INC. | $163.15 | 2019-2025 | Trodelvy |
| Exelixis INC. | $154.65 | 2019-2025 | Cabometyx |
| Genentech USA, INC. | $151.56 | 2019-2024 | Lunsumio, Polivy, Columvi |
| Rigel Pharmaceuticals, INC. | $118.09 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Array Biopharma INC | $114.68 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Servier Pharmaceuticals LLC | $108.37 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $96.26 | 2024-2025 | Onivyde |
| Geron Corporation | $94.99 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $86.57 | 2019-2025 | Fruzaqla, Iclusig |
| Beone Medicines USA, INC. | $82.37 | 2025 | Brukinsa, Tevimbra |
| Emd Serono, INC. | $81.99 | 2019-2025 | |
| Stemline Therapeutics INC. | $81.24 | 2025 | Orserdu |
| Mirati Therapeutics, INC. | $76.87 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $73.07 | 2019-2025 | |
| Kite Pharma, INC. | $73.06 | 2022-2025 | Yescarta |
| Astellas Pharma US INC | $66.37 | 2020-2025 | Xtandi, Padcev |
| Regeneron Healthcare Solutions, INC. | $65.57 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $65.22 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.06 | 2019 | |
| Jazz Pharmaceuticals INC. | $62.03 | 2024-2025 | |
| Tempus Ai, INC | $59.48 | 2024 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $54.45 | 2024 | Monoferric |
| Glaxosmithkline, LLC. | $49.88 | 2023-2024 | Zejula, Jemperli, Ojjaara |
| Beigene USA, INC. | $39.44 | 2024-2025 | Tevimbra |
| Progenics Pharmaceuticals, INC. | $38.50 | 2023-2024 | Pylarify |
| Legend Biotech USA INC. | $31.26 | 2025 | Carvykti |
| Syndax Pharmaceuticals, INC. | $27.22 | 2025 | |
| Springworks Therapeutics, INC. | $26.68 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $25.92 | 2024 | Empaveli |
| Telix Pharmaceuticals | $24.78 | 2024 | Illuccix |
| Menarini Silicon Biosystems, INC. | $22.94 | 2024 | |
| Dendreon Pharmaceuticals LLC | $22.09 | 2024 | Provenge |
| Blueprint Medicines Corporation | $19.95 | 2024 | Ayvakit |
| Immunogen, INC. | $19.34 | 2023 | Elahere |
| Adc Therapeutics America, INC. | $15.85 | 2024 | |
| Coherus Oncology, INC. | $15.84 | 2024 | |
| Pharmaessentia USA Corporation | $15.66 | 2025 | Besremi |
| Foundation Medicine, INC. | $15.52 | 2019 | |
| Tolmar, INC. | $15.31 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $15.31 | 2025 | Rubraca |
| Karyopharm Therapeutics INC. | $13.29 | 2024 | Xpovio |
| Secura Bio, INC. | $13.03 | 2020 | |
| Verastem, INC. | $12.20 | 2019 | |
| Taiho Oncology, INC. | $11.75 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Langerak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.